Industry News
Anixa Biosciences Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial
– With no dose-limiting toxicities observed, treatment of second dose cohort to begin Excerpt from the Press Release: SAN JOSE, Calif., Oct. 13, 2023 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in partnership with Moffitt Cancer Center, it…
Read More
– Key Biomarker Activity Confirmed for Evaluation in Upcoming Phase 1 Study – Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that data from recent preclinical studies of the Company’s Gemini formulation demonstrated its therapeutic potential as a preventative therapy across multiple indications including infection…
Read More
Excerpt from the Press Release: SAN DIEGO, Oct. 13, 2023 /PRNewswire/ — Inmagene Biopharmaceuticals (“Inmagene”), a clinical stage biotechnology company developing innovative and differentiated therapies for immunological and inflammatory diseases, announced that the first patient has been dosed in a global multicenter Phase 2a study of IMG-007 in adult patients with AA. The study will…
Read More
– Results showing significant reductions in liver fat content and body weight, no loss of lean muscle mass, and improvement in key markers of metabolism and inflammation published in The Lancet Gastroenterology & Hepatology – – HU6 was well tolerated at once-daily oral doses with adverse events mainly mild or moderate in severity Excerpt from…
Read More
Excerpt from the Press Release: SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the Phase 1/2 dose escalation/dose expansion study of ONCT-534, the company’s dual-action androgen receptor inhibitor.…
Read More
Collaboration with OICR and capital from FACIT contributing to a growing hub of medical imaging research in Thunder Bay. Excerpt from the Press Release: When Sasha Bubon arrived in Thunder Bay in January 2010 to begin his master’s studies in physics at Lakehead University, he was starting a whole new chapter personally and scientifically. …
Read More
Excerpt from the Press Release: SAN FRANCISCO, CA and TAIPEI, TAIWAN / ACCESSWIRE / October 3, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company focusing on the discovery and development of innovative immuno-biomedicines to treat a wide variety of patients suffering from different solid tumors or hematological malignancies with significant unmet medical needs, today…
Read More
— Evorpacept is the first CD47 blocker to show activity in a global randomized study in solid tumors — Interim efficacy results showed the confirmed overall response rate for evorpacept combination treatment was 52% compared to 22% for control treatment Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) — ALX…
Read More
Company’s Artificial Intelligence Technology Shows Better Results in Early Detection and Patient Care Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in pulmonary embolism (PE) detection. Two studies have demonstrated the real-world clinical efficacy of Viz.ai’s PE Module…
Read More
– Phase 2a NASH protocol on track to be submitted to the IND in Q4 2023, enrollment expected to begin in Q1 2024 Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to…
Read More